Stocks and InvestingStocks and Investing
Fri, June 28, 2013
Thu, June 27, 2013
Wed, June 26, 2013
Tue, June 25, 2013
Mon, June 24, 2013
Fri, June 21, 2013
Thu, June 20, 2013
Wed, June 19, 2013
Tue, June 18, 2013
Mon, June 17, 2013
Fri, June 14, 2013
Thu, June 13, 2013
Wed, June 12, 2013
Tue, June 11, 2013
Mon, June 10, 2013
Fri, June 7, 2013
Thu, June 6, 2013
Wed, June 5, 2013
Tue, June 4, 2013
Mon, June 3, 2013
Fri, May 31, 2013
Thu, May 30, 2013
Wed, May 29, 2013
Tue, May 28, 2013
Fri, May 24, 2013
Thu, May 23, 2013
Wed, May 22, 2013
Tue, May 21, 2013
Mon, May 20, 2013
Fri, May 17, 2013
Thu, May 16, 2013
Wed, May 15, 2013
Tue, May 14, 2013

David Amsellem Maintained (SUPN) at Buy with Decreased Target to $13 on, May 14th, 2013


Published on 2024-10-25 02:38:30 - WOPRAI, David Amsellem
  Print publication without navigation


David Amsellem of Piper Sandler, Maintained "Supernus Pharmaceuticals, Inc." (SUPN) at Buy with Decreased Target from $14 to $13 on, May 14th, 2013.

David has made no other calls on SUPN in the last 4 months.



There is 1 other peer that has a rating on SUPN. Out of the 1 peers that are also analyzing SUPN, 0 agree with David's Rating of Hold.



This is the rating of the analyst that currently disagrees with David


  • David Steinberg of "Jefferies" Initiated at Strong Buy and Held Target at $13 on, Tuesday, March 5th, 2013